1. Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents. (August 1996) Authors: Dean, N. M.; McKay, R.; Miraglia, L.; Geigert, T.; Müllert, M.; Fabbro, D.; Bennett, C. F. Journal: Biochemical Society transactions Issue: Volume 24:Number 3(1996) Page Start: 623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Early preclinical development of PQR309, a novel balanced dual PI3K/mTOR inhibitor for treatment of various cancer types. (16th October 2015) Authors: Ettlin, R.; Dieterle, W.; Fabbro, D.; Hebeisen, P.; Beaufils, F.; Hillmann, P.; Stumm, M.; Dimitrijević, S.; Wymann, M.; Cmiljanovic, N.; Giese, B.; Cmiljanovic, V. Journal: Toxicology letters Issue: Volume 238(2015)Supplement Page Start: S337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Arribas, A.; Rinaldi, A.; Spriano, F.; Tarantelli, C.; Gaudio, E.; Bernasconi, E.; Hillmann, P.; Kwee, I.; Stathis, A.; Fabbro, D.; Stüssi, G.; Zucca, E.; Rossi, D.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Second-generation antisense oligonucleotides: structure—activity relationships and the design of improved signal-transduction inhibitors. (August 1996) Authors: Altmann, K.-H.; Fabbro, D.; Dean, N. M.; Geiger, T.; Monia, B. P.; Müllert, M.; Nicklin, P. Journal: Biochemical Society transactions Issue: Volume 24:Number 3(1996) Page Start: 630 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas. (December 2016) Authors: Tarantelli, C.; Gaudio, E.; Hillmann, P.; Spriano, F.; Rinaldi, A.; Kwee, I.; Cascione, L.; Fabbro, D.; Stathis, A.; Zucca, E.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗